journal
MENU ▼
Read by QxMD icon Read
search

Diabetes Technology & Therapeutics

journal
https://www.readbyqxmd.com/read/28328234/quantification-of-basal-insulin-peglispro-and-human-insulin-in-adipose-tissue-interstitial-fluid-by-open-flow-microperfusion
#1
Katrin Tiffner, Beate Boulgaropoulos, Christian Höfferer, Thomas Birngruber, Niels Porksen, Helle Linnebjerg, Parag Garhyan, Eric Chen Quin Lam, Mary Pat Knadler, Thomas R Pieber, Frank Sinner
BACKGROUND: Restoration of the physiologic hepatic-to-peripheral insulin gradient may be achieved by either portal vein administration or altering insulin structure to increase hepatic specificity or restrict peripheral access. Basal insulin peglispro (BIL) is a novel, PEGylated basal insulin with a flat pharmacokinetic and glucodynamic profile and altered hepatic-to-peripheral action gradient. We hypothesized reduced BIL exposure in peripheral tissues explains the latter, and in this study assessed the adipose tissue interstitial fluid (ISF) concentrations of BIL compared with human insulin (HI)...
March 22, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28300428/empa-s-new-clothes-the-untold-story-of-the-empa-reg-outcome-trial
#2
Aus Alzaid
It is no secret that the diabetes community has been yearning for good news for quite some time. One outstanding issue undermining effective diabetes management has been the lack of demonstrable effects of glycemic interventions on cardiovascular (CV) outcome in people with type 2 diabetes. This, however, seems to have changed recently after the publication of the Empa-Reg Outcome Trial. The study reported an impressive reduction in CV deaths that was observed within weeks of treatment with the diabetes agent, Empagliflozin...
March 16, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28296467/comparison-of-insulin-pump-therapy-and-multiple-daily-injections-insulin-regimen-in-patients-with-type-1-diabetes-during-ramadan-fasting
#3
Reem Alamoudi, Maram Alsubaiee, Ali Alqarni, Yousef Saleh, Saleh Aljaser, Abdul Salam, Mohsen Eledrisi
INTRODUCTION: Fasting Ramadan carries a high risk for patients with type 1 diabetes (T1DM). Data on the optimum insulin regimen in these patients are limited. OBJECTIVES: To compare glucose profiles in patients with T1DM who use continuous subcutaneous insulin infusion (CSII) compared with those who use multiple daily injections (MDI) insulin regimen during Ramadan fast. The primary outcome was rates of hypoglycemia. Other outcomes included glycemic control, number of days needed to break fasting, and acute glycemic complications...
March 15, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28287834/retrofitting-real-life-dexcom-g5-data
#4
Simone Del Favero, Andrea Facchinetti, Giovanni Sparacino, Claudio Cobelli
BACKGROUND: We proposed in 2014 a retrofitting algorithm to retrospectively increase the accuracy of continuous glucose monitoring (CGM) data by using some blood glucose (BG) measurements. The method proved effective on Dexcom SEVEN Plus when about 10 highly accurate YSI measurements/session were available. In this study, we test the method on Dexcom G5 sensor in a more realistic setup, where only five capillary BG measurements (self-monitoring blood glucose [SMBG]) per 12 h-session are available...
March 13, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28282241/pregnancy-outcomes-and-insulin-requirements-in-women-with-type-1-diabetes-treated-with-continuous-subcutaneous-insulin-infusion-and-multiple-daily-injections-cohort-study
#5
Sally K Abell, Matthew Suen, Anthony Pease, Jacqueline A Boyle, Georgia Soldatos, John Regan, Euan M Wallace, Helena J Teede
BACKGROUND: We aimed to compare glycemic control, insulin requirements, and outcomes in women with type 1 diabetes in pregnancy treated with continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI). METHODS: A retrospective cohort study was conducted of singleton pregnancies (>20 weeks gestation) in women with type 1 diabetes (2010-2015) at a specialist multidisciplinary maternity network in Australia. Antenatal characteristics, diabetes history and treatment details, and maternal and neonatal outcomes were compared for women with type 1 diabetes using CSII and MDI...
March 10, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28282219/a-fixed-ratio-combination-of-insulin-degludec-and-liraglutide-ideglira-reduces-glycemic-fluctuation-and-brings-more-patients-with-type-2-diabetes-within-blood-glucose-target-ranges
#6
Allen B King, Athena Philis-Tsimikas, Eric S Kilpatrick, Irene H Langbakke, Kamilla Begtrup, Tina Vilsbøll
BACKGROUND: Reducing glycemic fluctuation is important for optimal diabetes management. This post hoc analysis examined glycemic fluctuations and the proportion of subjects achieving recommended blood glucose targets with the fixed ratio combination of insulin degludec and liraglutide (IDegLira) compared to insulin degludec (IDeg) and liraglutide alone. METHODS: We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability...
March 10, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28249123/clinical-experience-with-u-500-regular-insulin-by-multiple-daily-injections-and-continuous-subcutaneous-insulin-infusion
#7
Lisa T Meade, Rebecca C Tart, Donnie Nuzum
BACKGROUND: The effectiveness of U-500 regular insulin was assessed in patients with type 2 diabetes who were previously treated with U-100 insulin. METHODS: A retrospective chart review was conducted on all patients who were prescribed U-500 insulin between January 2012 and December 2013. The primary outcome measure was change in glycosylated hemoglobin (A1C) 1 year after switching from U-100 insulin to U-500 regular insulin. Secondary outcomes included change in body weight, total daily insulin dose, number of daily injections, and episodes of hypoglycemia...
March 1, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28245152/real-world-use-and-self-reported-health-outcomes-of-a-patient-designed-do-it-yourself-mobile-technology-system-for-diabetes-lessons-for-mobile-health
#8
Joyce M Lee, Mark W Newman, Achamyeleh Gebremariam, Preciosa Choi, Dana Lewis, Weston Nordgren, John Costik, James Wedding, Benjamin West, Nancy Benovich Gilby, Christopher Hannemann, Josh Pasek, Ashley Garrity, Emily Hirschfeld
BACKGROUND: The aim of this study is to compare demographic/disease characteristics of users versus nonusers of a do-it-yourself (DIY) mobile technology system for diabetes (Nightscout), to describe its uses and personalization, and to evaluate associated changes in health behaviors and outcomes. METHODS: A cross-sectional, household-level online survey was used. Of 1268 household respondents who were members of the CGM in the Cloud Facebook group, there were 1157 individuals with diabetes who provided information about Nightscout use...
February 28, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28231029/unintended-insulin-pump-delivery-in-hyperbaric-conditions
#9
Federico Bertuzzi, Basilio Pintaudi, Matteo Bonomo, Fabio Garuti
AIMS/HYPOTHESIS: Unintended pump insulin delivery was reported to occur as a consequence of decreased atmospheric pressure, probably mediated by air bubble formation and the expansion of existing bubbles. This observation has been used to explain some hypoglycemic episodes occurring in patients on insulin pump treatment in between 1 and 1 h 45 min after the flight takeoff. New models of insulin pumps have been introduced in the market, most of them are waterproof certified. It is not clear if in these new pumps the influence of atmospheric pressure changes on the insulin delivery is still present...
February 23, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28225633/accuracy-evaluation-of-four-blood-glucose-monitoring-systems-in-the-hands-of-intended-users-and-trained-personnel-based-on-iso-15197-requirements
#10
Guido Freckmann, Annette Baumstark, Nina Jendrike, Delia Rittmeyer, Stefan Pleus, Cornelia Haug
BACKGROUND: Self-monitoring of blood glucose (BG) is an integral part in the therapy of people with diabetes, which is why blood glucose monitoring systems (BGMS) have to fulfill minimum accuracy requirements. However, accuracy is often assessed by trained operators, although such assessments do not necessarily allow for drawing conclusions on accuracy in the hands of lay users. METHODS: The accuracy of 4 different BGMS (Accu-Chek(®) Active, Accu-Chek(®) Performa, Contour(®)Plus, and OneTouch(®) SelectSimple™) in the hands of lay users and trained study personnel was assessed in this study...
February 22, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28221814/an-amperometric-glucose-sensor-integrated-into-an-insulin-delivery-cannula-in-vitro-and-in-vivo-evaluation
#11
W Kenneth Ward, Gabriel Heinrich, Matthew Breen, Sheila Benware, Nicole Vollum, Kristin Morris, Chad Knutsen, Joseph D Kowalski, Scott Campbell, Jerry Biehler, Mark S Vreeke, Scott M Vanderwerf, Jessica R Castle, Robert S Cargill
BACKGROUND: Labeling prohibits delivery of insulin at the site of subcutaneous continuous glucose monitoring (CGM). Integration of the sensing and insulin delivery functions into a single device would likely increase the usage of CGM in persons with type 1 diabetes. METHODS: To understand the nature of such interference, we measured glucose at the site of bolus insulin delivery in swine using a flexible electrode strip that was laminated to the outer wall of an insulin delivery cannula...
February 21, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28221823/evaluation-of-a-predictive-low-glucose-management-system-in-clinic
#12
Bruce A Buckingham, Timothy S Bailey, Mark Christiansen, Satish Garg, Stuart Weinzimer, Bruce Bode, Stacey M Anderson, Ron Brazg, Trang Ly, Francine R Kaufman
BACKGROUND: Predictions based on continuous glucose monitoring (CGM) data are the basis for automatic suspension and resumption of insulin delivery by a predictive low-glucose management feature termed "suspend before low," which is part of the Medtronic MiniMed(®) 640G combined insulin pump and CGM system. This study assessed the safety and performance characteristics of the system in an in-clinic setting at eight sites. MATERIALS AND METHODS: In-clinic standardized increases in basal insulin delivery rates were used to induce nocturnal hypoglycemia in subjects (14-75 years) with type 1 diabetes wearing the MiniMed 640G system...
February 16, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28287847/the-first-hybrid-closed-loop-insulin-pump-will-it-meet-its-potential
#13
Irl B Hirsch
No abstract text is available yet for this article.
March 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28287846/will-the-first-approved-automated-insulin-delivery-system-be-a-game-changer-in-type-1-diabetes-management
#14
Jessica R Castle
No abstract text is available yet for this article.
March 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28263665/a-clinical-trial-of-the-accuracy-and-treatment-experience-of-the-flash-glucose-monitor-freestyle-libre-in-adults-with-type-1-diabetes
#15
Arndís F Ólafsdóttir, Stig Attvall, Ulrika Sandgren, Sofia Dahlqvist, Aldina Pivodic, Stanko Skrtic, Elvar Theodorsson, Marcus Lind
BACKGROUND: In Sweden, FreeStyle Libre a flash glucose monitoring system came onto the market in 2014 as a complement to self-monitoring of blood glucose. The aim of this study was to evaluate the accuracy and treatment experience of the FreeStyle Libre system. METHODS: Fifty-eight adults with type 1 diabetes used FreeStyle Libre for 10-14 days and measured capillary blood glucose levels with the HemoCue blood glucose measurement system at least six times a day simultaneously...
March 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28249120/acceptance-of-fgm-or-cgm-in-clinical-decision-making-and-patient-preference-where-do-we-go-from-here
#16
Roger S Mazze
No abstract text is available yet for this article.
March 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28248127/a-pediatric-intensive-care-unit-bedside-computer-clinical-decision-support-protocol-for-hyperglycemia-is-feasible-safe-and-offers-advantages
#17
Eliotte L Hirshberg, Michael J Lanspa, Emily L Wilson, Katherine A Sward, Al Jephson, Gitte Y Larsen, Alan H Morris
BACKGROUND: Computer clinical decision support (CDS) systems are uncommon in the pediatric intensive care unit (PICU), despite evidence suggesting they improve outcomes in adult ICUs. We reasoned that a bedside CDS protocol for intravenous insulin titration, eProtocol-insulin, would be feasible and safe in critically ill children. METHODS: We retrospectively reviewed data from non-diabetic children admitted to the PICU with blood glucose (BG) ≥140 mg/dL who were managed with intravenous insulin by either unaided clinician titration or eProtocol-insulin...
March 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28221815/soliciting-and-responding-to-patients-questions-about-diabetes-through-online-sources
#18
Colleen E Crangle, Colin Bradley, Paul F Carlin, Robert J Esterhay, Roy Harper, Patricia M Kearney, Kate Lorig, Vera J C McCarthy, Michael F McTear, Mark S Tuttle, Jonathan G Wallace, Eileen Savage
When patients cannot get answers from health professionals or retain the information given, increasingly they search online for answers, with limited success. Researchers from the United States, Ireland, and the United Kingdom explored this problem for patients with type 2 diabetes mellitus (T2DM). In 2014, patients attending an outpatient clinic (UK) were asked to submit questions about diabetes. Ten questions judged representative of different types of patient concerns were selected by the researchers and submitted to search engines within trusted and vetted websites in the United States, Ireland, and the United Kingdom...
March 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28177779/the-use-of-electrochemiluminescence-assays-to-predict-autoantibody-and-glycemic-progression-toward-type-1-diabetes-in-individuals-with-single-autoantibodies
#19
Jay M Sosenko, Liping Yu, Jay S Skyler, Jeffrey P Krischer, Peter A Gottlieb, David Boulware, Dongmei Miao, Jerry P Palmer, Andrea K Steck
BACKGROUND: Electrochemiluminescence (ECL) assays have shown promise for enhancing the prediction of type 1 diabetes (T1D) with autoantibodies. We thus studied relatives of T1D patients to determine whether ECL assays can be used to refine risk assessments for T1D among individuals either positive for single GADA or single mIAA autoantibodies. SUBJECTS AND METHODS: TrialNet Pathway to Prevention (PTP) study participants with either GADA or mIAA single autoantibodies were tested for ECL positivity during their participation in the TrialNet PTP study...
March 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28135116/an-expert-opinion-on-advanced-insulin-pump-use-in-youth-with-type-1-diabetes
#20
Bruce W Bode, Francine R Kaufman, Nan Vint
Among children and adolescents with type 1 diabetes mellitus, the use of insulin pump therapy has increased since its introduction in the early 1980s. Optimal management of type 1 diabetes mellitus depends on sufficient understanding by patients, their families, and healthcare providers on how to use pump technology. The goal for the use of insulin pump therapy should be to advance proficiency over time from the basics taught at the initiation of pump therapy to utilizing advanced settings to obtain optimal glycemic control...
March 2017: Diabetes Technology & Therapeutics
journal
journal
34712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"